Search

Your search keyword '"Ozakbas S."' showing total 366 results
Start Over Author "Ozakbas S."
366 results on '"Ozakbas S."'

101. Predicting long-term sustained disability progression in multiple sclerosis

Author

Sharmin, S., Malpas, C., Horakova, D., Havrdova, E. K., Izquierdo, G., Eichau, S., Trojano, M., Prat, A., Girard, M., Duquette, P., Onofrj, M., Lugaresi, A., Grand Maison, F., Grammond, P., Sola, P., Ferraro, D., Terzi, M., Hupperts, R., Alroughani, R., Boz, C., Shaygannejad, V., Pesch, V., Cartechini, E., Kappos, L., Lechner-Scott, J., Bergamaschi, R., Recai Turkoglu, Solaro, C., Ramo-Tello, C., Iuliano, G., Granella, F., Wijmeersch, B., Spitaleri, D., Bolanos, R. F., Slee, M., Mccombe, P., Prevost, J., Ampapa, R., Ozakbas, S., Sanchez-Menoyo, J. L., Soysal, A., Vucic, S., Petersen, T., Verheul, F., Butler, E., Hodgkinson, S., Sidhom, Y., Gouider, R., Butzkueven, H., and Kalincik, T.

Published
2019

102. MS cohorts and treatment utilization in academic centres in the Middle East

Author

Moradi, N., Sharmin, S., Malpas, C., Ozakbas, S., Shaygannejad, V., Alroughani, R., Kalincik, T., and Ondokuz Mayıs Üniversitesi

Abstract

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS -- SEP 11-13, 2019 -- Stockholm, SWEDEN Turkoglu, Recai/0000-0001-9724-851X; Altintas, Ayse/0000-0002-8524-5087 WOS: 000485303101329 … European Comm Treatment & Res Multiple Sclerosis, Congrex Switzerland Ltd

Published
2019

103. Real world efficacy and safety of teriflunomide in multiple sclerosis: an observational study with four years follow-up

Author

Boz, C., Terzi, M., Ozakbas, S., Yuceyar, N., Efendi, H., Balci, B. P., Kizilay, F., Çukurova Üniversitesi, and Ondokuz Mayıs Üniversitesi

Abstract

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS -- SEP 11-13, 2019 -- Stockholm, SWEDEN Yetkin, Mehmet Fatih/0000-0002-2541-7107; Turkoglu, Recai/0000-0001-9724-851X WOS: 000485303103364 … European Comm Treatment & Res Multiple Sclerosis, Congrex Switzerland Ltd

Published
2019

104. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

Author

Brown J, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson O, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N, Onofrj M, De Luca G, Di Tommaso V, Travaglini D, Pietrolongo E, di Ioia M, Farina D, Mancinelli L, Hodgkinson S, Oreja-Guevara C, Boz C, Prevost J, Olascoaga J, Van Wijmeersch B, Barnett M, Verheul F, Rojas J, Spitaleri D, Rio M, Taylor B, Sanchez-Menoyo J, Ramo-Tello C, Solaro C, Csepany T, Iuliano G, Skibina O, Petersen T, Bolanos R, Sidhom Y, Riadh, Vucic S, Macdonell R, Sempere A, Simo M, Kister I, Shuey N, Radek, Dominguez J, Amato M, Saladino M, Kermode A, Butler E, Moore F, Hughes S, McDonnell G, Piroska I, Yamout B, Soysal A, Ozakbas S, Zwanikken C, and MSBase Study Grp

Abstract

IMPORTANCE Within 2 decades of onset, 80% of untreated patients with relapsing-remitting multiple sclerosis (MS) convert to a phase of irreversible disability accrual termed secondary progressiveMS. The association between disease-modifying treatments (DMTs), and this conversion has rarely been studied and never using a validated definition. OBJECTIVE To determine the association between the use, the type of, and the timing of DMTs with the risk of conversion to secondary progressive MS diagnosed with a validated definition. DESIGN, SETTING, AND PARTICIPANTS Cohort study with prospective data from 68 neurology centers in 21 countries examining patients with relapsing-remittingMS commencing DMTs (or clinical monitoring) between 1988-2012 with minimum 4 years' follow-up. EXPOSURES The use, type, and timing of the following DMTs: interferon beta, glatiramer acetate, fingolimod, natalizumab, or alemtuzumab. After propensity-score matching, 1555 patients were included (last follow-up, February 14, 2017). MAIN OUTCOME AND MEASURE Conversion to objectively defined secondary progressiveMS. RESULTS Of the 1555 patients, 1123 were female (mean baseline age, 35 years [SD, 10]). Patients initially treated with glatiramer acetate or interferon beta had a lower hazard of conversion to secondary progressiveMS than matched untreated patients (HR, 0.71; 95% CI, 0.61-0.81; P

Published
2019

105. Real-world experience with Ocrelizumab in the MSBase Registry

Author

Butzkueven, H., Spelman, T., Patti, F., Ozakbas, S., Eichau, S., Alroughani, R., Craveiro, L., and Ondokuz Mayıs Üniversitesi

Abstract

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS -- SEP 11-13, 2019 -- Stockholm, SWEDEN Laureys, Guy/0000-0002-1708-4373 WOS: 000485303102197 … European Comm Treatment & Res Multiple Sclerosis, Congrex Switzerland Ltd F. Hoffmann-La Roche Ltd.Hoffmann-La Roche Sponsored by F. Hoffmann-La Roche Ltd. Editorial assistance was provided by Articulate Science, UK.

Published
2019

106. Determinants of MS re-activation after discontinuing therapies.

Author

Fernandez Bolanos R., Kubala Havrdova E., Izquierdo G., Eichau S., Prat A., Girard M., Duquette P., Trojano M., Grammond P., Lugaresi A., Onofrj M., Ozakbas S., Verheul F., Ramo-Tello C., Turkoglu R., Horakova D., Macdonell R., Soysal A., Moreno Betancur M., Kalincik T., Butler E., Husin H., Wallace J., Malpas C., Sharmin S., Butzkueven H., Sola P., Ferraro D., Alroughani R., Grand'Maison F., Terzi M., Lechner-Scott J., Boz C., Hupperts R., Shaygannejad V., Bergamaschi R., Pucci E., Van Pesch V., Hodgkinson S., McCombe P., Granella F., Slee M., Van Wijmeersch B., Karabudak R., Prevost J., Petersen T., Spitaleri D., Barnett M., Solaro C., Iuliano G., Fernandez Bolanos R., Kubala Havrdova E., Izquierdo G., Eichau S., Prat A., Girard M., Duquette P., Trojano M., Grammond P., Lugaresi A., Onofrj M., Ozakbas S., Verheul F., Ramo-Tello C., Turkoglu R., Horakova D., Macdonell R., Soysal A., Moreno Betancur M., Kalincik T., Butler E., Husin H., Wallace J., Malpas C., Sharmin S., Butzkueven H., Sola P., Ferraro D., Alroughani R., Grand'Maison F., Terzi M., Lechner-Scott J., Boz C., Hupperts R., Shaygannejad V., Bergamaschi R., Pucci E., Van Pesch V., Hodgkinson S., McCombe P., Granella F., Slee M., Van Wijmeersch B., Karabudak R., Prevost J., Petersen T., Spitaleri D., Barnett M., Solaro C., and Iuliano G.

Abstract

Introduction: A decision to discontinue MS immunotherapies is common in clinical practice - whether in order to switch to another therapy or at an advanced stage of progressive MS without relapses. The evidence regarding individual risk of MS re-activation after treatment discontinuation is limited. Aim(s): To evaluate associations of demographic and clinical patient characteristics with the risk of relapses after discontinuing treatment. Both overall and treatment-specific associations are explored. Method(s): Using the global MSBase registry, we identified all patients who discontinued MS immunotherapy after >=3 months on treatment, with the recorded disability score (EDSS) at the time of discontinuing treatment, and prospectively recorded follow-up of >=6 months. The probability of experiencing a relapse after discontinuing treatment, conditional on patient characteristics, was analysed with Cox proportional hazards model. Differences in these associations among different therapies were studied with interaction terms. Result(s): 24,989 episodes of treatment discontinuation were recorded from 17,871 patients (74% female, mean age at discontinuation 39 years, 88% relapsing-remitting MS, mean MS duration 10 years, median EDSS 2.5). The patient characteristics associated with a lower hazard of MS re-activation were male sex (b=0.87, p< 0.001), older age (b=0.98, p< 0.001), MS duration (b=1.01, p< 0.001), secondary progressive MS (b=0.73, p< 0.001), longer treatment duration (0.95, p< 0.001), greater number of prior treatments (1: b=0.62, p< 0.001; >=2: b=0.39, p< 0.001) and greater number of relapses during the previous year (1: b=1.30, p< 0.001; >=2: b=1.62, p< 0.001). The characteristics associated with a greater risk of MS re-activation were clinically isolated syndrome (b=1.87, p< 0.001) and greater EDSS (4-5.5: b=1.41, p< 0.001; >=6: b=1.17, p=0.001). Therapies used more recently (dimethyl fumarate, fingolimod, natalizumab) tended to be associated with a lower h

Published
2019

107. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.

Author

Spelman T., Karabudak R., Butler E., Vucic S., Jokubaitis V., Butzkueven H., Kalincik T., Kubala Havrdova E., Horakova D., Izquierdo G., Prat A., Girard M., Duquette P., Grammond P., Onofrj M., Lugaresi A., Ozakbas S., Kappos L., Kuhle J., Terzi M., Lechner-Scott J., Boz C., Grand'maison F., Prevost J., Sola P., Ferraro D., Granella F., Trojano M., Bergamaschi R., Pucci E., Turkoglu R., McCombe P.A., Pesch V.V., Van Wijmeersch B., Solaro C., Ramo-Tello C., Slee M., Alroughani R., Yamout B., Shaygannejad V., Spitaleri D., Sanchez-Menoyo J.L., Ampapa R., Hodgkinson S., Spelman T., Karabudak R., Butler E., Vucic S., Jokubaitis V., Butzkueven H., Kalincik T., Kubala Havrdova E., Horakova D., Izquierdo G., Prat A., Girard M., Duquette P., Grammond P., Onofrj M., Lugaresi A., Ozakbas S., Kappos L., Kuhle J., Terzi M., Lechner-Scott J., Boz C., Grand'maison F., Prevost J., Sola P., Ferraro D., Granella F., Trojano M., Bergamaschi R., Pucci E., Turkoglu R., McCombe P.A., Pesch V.V., Van Wijmeersch B., Solaro C., Ramo-Tello C., Slee M., Alroughani R., Yamout B., Shaygannejad V., Spitaleri D., Sanchez-Menoyo J.L., Ampapa R., and Hodgkinson S.

Abstract

Objective Oral immunotherapies have become a standard treatment in relapsing-remitting multiple sclerosis. Direct comparison of their effect on relapse and disability is needed. Methods We identified all patients with relapsing-remitting multiple sclerosis treated with teriflunomide, dimethyl fumarate or fingolimod, with minimum 3-month treatment persistence and disability follow-up in the global MSBase cohort study. Patients were matched using propensity scores. Three pairwise analyses compared annualised relapse rates and hazards of disability accumulation, disability improvement and treatment discontinuation (analysed with negative binomial models and weighted conditional survival models, with pairwise censoring). Results The eligible cohorts consisted of 614 (teriflunomide), 782 (dimethyl fumarate) or 2332 (fingolimod) patients, followed over the median of 2.5 years. Annualised relapse rates were lower on fingolimod compared with teriflunomide (0.18 vs 0.24; p=0.05) and dimethyl fumarate (0.20 vs 0.26; p=0.01) and similar on dimethyl fumarate and teriflunomide (0.19 vs 0.22; p=0.55). No differences in disability accumulation (p>=0.59) or improvement (p>=0.14) were found between the therapies. In patients with >=3-month treatment persistence, subsequent discontinuations were less likely on fingolimod than teriflunomide and dimethyl fumarate (p<0.001). Discontinuation rates on teriflunomide and dimethyl fumarate were similar (p=0.68). Conclusion The effect of fingolimod on relapse frequency was superior to teriflunomide and dimethyl fumarate. The effect of the three oral therapies on disability outcomes was similar during the initial 2.5 years on treatment. Persistence on fingolimod was superior to the two comparator drugs.Copyright © 2019 Author(s) (or their employer(s)). No commercial re-use. See rights and permissions. Published by BMJ.

Published
2019

108. Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remetting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry

Author

Grammond, P., Prat, A., Girard, M., Duquette, P., Onofrj, M., Lugaresi, A., Granella, F., Izquierdo, G., Horakova, D., Butzkueven, H., McCombe, P., Cartechini, E., Karabudak, R., Boz, C., Van Wijmeersch, B., Van Pesch, V., Sola, P., Ferrero, D., Sa, M. J., Harvrdova, E. K., Spelman, T., Kalincik, T., Lechner-Scott, J., Grand'Maison, F., Terzi, M., and Ozakbas, S.

Published
2018

110. Disability outcomes in patients with early cerebellar symptoms in multiple sclerosis

Author

Le, M. V. H., Malpas, C., Sharmin, S., Horakova, D., Havrdova, E. K., Trojano, M., Izquierdo, G., Eichau, S., Ozakbas, S., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Alroughani, R., Bergamaschi, R., Sola, P., Grammond, P., Grand Maison, F., Terzi, M., Boz, C., Hupperts, R., Butzkueven, H., Walt, A., Pucci, E., Granella, F., Pesch, V., Soysa, A., Yamout, B., Lechner-Scott, J., Spitaleri, D., Ampapa, R., Recai Turkoglu, Iuliano, G., Ramo-Tello, C., Sanchez-Menoyo, J. L., Gouider, R., Shaygannejad, V., Prevost, J., Altintas, A., Fragoso, Y., Mccombe, P., Petersen, T., Slee, M., Barnett, M., Vucic, S., and Kalincik, T.

Published
2018

117. Comparison of fingolimod and teriflunomide on the basis of relapse, magnetic resonance imaging and cognition following the switch from injectables in patients with stable multiple sclerosis

Author

Ozakbas, S., Cinar, B. Piri, Babayev, C., and Zonguldak Bülent Ecevit Üniversitesi

Abstract

34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) -- OCT 10-12, 2018 -- Berlin, GERMANY, WOS: 000446861402287, European Comm Treatment & Res Multiple Sclerosis

Published
2018

118. Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis

Author

Chitnis, T, Arnold, Dl, Banwell, B, Brück, W, Ghezzi, A, Giovannoni, G, Greenberg, B, Krupp, L, Rostásy, K, Tardieu, M, Waubant, E, Wolinsky, Js, Bar-Or, A, Stites, T, Chen, Y, Putzki, N, Merschhemke, M, Gärtner, Collaborators (85): Kornberg A, J, Bajer-Kornek, B, Likhachev, S, Pereira Gomes Neto, A, Diniz, D, Paz, J, Alvarenga, R, Bojinova-Tchamova, V, Mah, J, Venkateswaran, S, Hafner, K, Gross-Paju, K, Brochet, B, Cheuret, E, Rivier, F, Deiva, K, Milh, M, Blaschek, A, Trollmann, R, Korinthenberg, R, Luecke, T, Ziemssen, T, Pozzilli, C, Patti, F, Comi, G, Marfia, G, Grimaldi, L, Trojano, M, Zaffaroni, M, Capra, R, Brescia Morra, V, Rozentals, G, Laurynaitiene, J, Vaiciene-Magistris, N, Castro Farfan, F, Quinones, S, Steinborn, B, Ujma-Czapska, B, Stasiolek, M, Jasinski, M, Craiu, D, Boyko, A, Kairbekova, E, Khabirov, F, Kuzenkova, L, Malkova, N, Nikolic, D, Jancic, J, Gebauer-Bukurov, K, Payerova, J, Gascon Jiménez, F, Izquierdo Ayuso, G, Mendibe Bilbao, M, Hintzen, R, Fernandez Sanchez VE, Meca Lallana, V, Montalban Gairin, X, Nordborg, K, Anlar, B, Yalcinkaya, C, Gucuyener, K, Terzi, M, Ozakbas, S, Yilmaz, U, Makedonska, I, Prokopenko, K, Tantsura, L, Moskovko, S, Kobys, T, Muratova, T, Nehrych, T, Prykhodko, T, Hemingway, C, Wassmer, E, Shetty, J, Desai, J, Waldman, A, Chinea Martinez, A, Ness, J, Rammohan, K, Lloyd, M, Williams, M, Ayala, R, Davis, R, Bhise, V, Brigham & Women’s Hospital [Boston] (BWH), Harvard Medical School [Boston] (HMS), McConnell Brain Imaging Centre (MNI), Montreal Neurological Institute and Hospital, McGill University = Université McGill [Montréal, Canada]-McGill University = Université McGill [Montréal, Canada], University of Pennsylvania [Philadelphia], Immunologie antivirale systémique et cérébrale, Université Paris-Sud - Paris 11 (UP11)-IFR93-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), and Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)

Subjects
0301 basic medicine, [SDV]Life Sciences [q-bio], Administration, Oral, administration, oral, adolescent, brain, child, female, fingolimod hydrochloride, headache, humans, immunologic factors, infection, injections, intramuscular, interferon-beta, leukopenia, magnetic resonance imaging, male, multiple sclerosis, relapsing-remitting, secondary prevention, medicine (all), law.invention, 0302 clinical medicine, Randomized controlled trial, Interferon, law, Medicine, Secondary prevention, General Medicine, Fingolimod, 3. Good health, Settore MED/26 - Neurologia, medicine.drug, medicine.medical_specialty, Infections, Injections, Intramuscular, Adolescent, Brain, Child, Female, Fingolimod Hydrochloride, Headache, Humans, Immunologic Factors, Infection, Interferon-beta, Leukopenia, Magnetic Resonance Imaging, Male, Multiple Sclerosis, Relapsing-Remitting, Secondary Prevention, 03 medical and health sciences, Internal medicine, business.industry, Multiple sclerosis, Interferon beta-1a, medicine.disease, Clinical trial, 030104 developmental biology, Multicenter study, business, 030217 neurology & neurosurgery
Abstract

International audience; BACKGROUND: Treatment of patients younger than 18 years of age with multiple sclerosis has not been adequately examined in randomized trials. We compared fingolimod with interferon beta-1a in this population. METHODS: In this phase 3 trial, we randomly assigned patients 10 to 17 years of age with relapsing multiple sclerosis in a 1:1 ratio to receive oral fingolimod at a dose of 0.5 mg per day (0.25 mg per day for patients with a body weight of

Published
2018

122. Effectiveness of fingolimod, dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis: a comparative longitudinal study

Author

Kalincik, T., Spelman, T., Jokubaitis, V., Horakova, D., Havrdova, E., Izquierdo, G., Prat, A., Girard, M., Duquette, P., Lugaresi, A., Grammond, P., Alroughani, R., Lechner-Scott, J., Prevost, J., Terzi, M., Grand Maison, F., Boz, C., Trojano, M., Wijmeersch, B., Pucci, E., Granella, F., Recai Turkoglu, Sola, P., Ferraro, D., Mccombe, P., Solaro, C., Pesch, V., Ozakbas, S., Slee, M., Spitaleri, D., Sanchez-Menoyo, J. L., Ampapa, R., Hodgkinson, S., Karabudak, R., Vucic, S., and Butzkueven, H.

Published
2017

127. Prognostic value of MRI activity in treatment failure

Author

Grammond, P., Alroughani, R., Sola, P., Ferraro, D., Ozakbas, S., Lugaresi, A., Lechner-Scott, J., Kalincik, T., Butzkueven, H., Sormani, M. P., Jokubaitis, V., Vucic, S., Spitaleri, D., Grand'Maison, F., Pucci, E., Boz, C., Van Wijmeersch, B., Sanchez-Menoyo, J. L., Trojano, M., Izquierdo, G., Kunchok, A. C., and Granella, F.

Published
2017

128. Timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosis

Author

Merkel, B., Jokubaitis, V., Spelman, T., Horakova, D., Havrdova, E., Trojano, M., Izquierdo, G., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Sola, P., Ferraro, D., Grammond, P., Hupperts, R., Bergamaschi, R., Alroughani, R., Boz, C., Terzi, M., Pucci, E., Pesch, V., Grand Maison, F., Fernandez-Bolanos, R., Lechner-Scott, J., Spitaleri, D., Shaygannejad, V., Iuliano, G., Granella, F., Solaro, C., Prevost, J., Petersen, T., Olascoaga, J., Cristina Ramo-Tello, Verheul, F., Mccombe, P., Slee, M., Sanchez-Menoyo, J. L., Cristiano, E., Ozakbas, S., Saladino, M. L., Ampapa, R., Vucic, S., Moore, F., Deri, N., Alkhaboori, J., Barnett, M., Walt, A., Butzkueven, H., and Kalincik, T.

Published
2017

130. Frequency of cognitive impairment in relapsing-remitting multiple sclerosis patients in Turkey and affecting factors

Author

Ozakbas, S., Turkoglu, R., Tamam, Y., Terzi, M., Taskapilioglu, O., Yucesan, C., Turkes, N., and Ondokuz Mayıs Üniversitesi

Abstract

7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS) -- OCT 25-28, 2017 -- Paris, FRANCE Turkoglu, Recai/0000-0001-9724-851X; WOS: 000413730203058 … European Comm Treatment & Res Multiple Sclerosis, Americas Comm Treatment & Res Multiple Sclerosis

Published
2017

135. Experience with fingolimod in clinical practice: clinical and MRI data

Author

Kosehasanogullari, G., Cinar, B. Piri, Ozakbas, S., Karakaptan, Y., and Belirlenecek

Subjects
geographic locations
Abstract

31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) -- OCT 07-10, 2015 -- Barcelona, SPAIN WOS: 000365729402342 … European Comm Treatment & Res Multiple Sclerosis

Published
2015

136. Prospective, multicenter study of monthly pulsed methylprednisolone treatment in patients with primary progressive multiple sclerosis: clinical and magnetic resonance imaging results

Author

Kahraman, T., Limoncu, H., Cinar, B. Piri, Kosehasanogullari, G., Ozakbas, S., and Belirlenecek

Subjects
geographic locations
Abstract

31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) -- OCT 07-10, 2015 -- Barcelona, SPAIN WOS: 000365729401429 … European Comm Treatment & Res Multiple Sclerosis

Published
2015

138. Social Cognition in Multiple Sclerosis: a Meta-Analysis

Author

Bora, E, Ozakbas, S, Velakoulis, D, Walterfang, M, Bora, E, Ozakbas, S, Velakoulis, D, and Walterfang, M

Abstract

Multiple sclerosis (MS) is associated with cognitive decline and impairment in social functioning. Accumulating evidence suggests that patients with MS are impaired in social cognition, including theory of mind (ToM) and emotion recognition. In this meta-analysis of 24 studies, facial emotion recognition and ToM performances of 989 patients with MS and 836 healthy controls were compared. MS was associated with significant impairments with medium effect sizes in ToM (d = 0.57) and facial emotion recognition (d = 0.61). Among individual emotions recognition of fear and anger were particularly impaired. The severity of social cognitive deficits was significantly associated with non-social cognitive impairment. These deficits in social cognition may underpin difficulties in social functioning in MS. However, there is a need for further studies investigating the longitudinal evolution of social cognitive deficits and their neural correlates in MS.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results